These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 2048219)
41. What we know and what we need to know about the role of endogenous CCK in psychostimulant sensitization. Beinfeld MC Life Sci; 2003 Jun; 73(6):643-54. PubMed ID: 12801586 [TBL] [Abstract][Full Text] [Related]
42. The CCK-A receptor antagonist devazepide but not the CCK-B receptor antagonist L-365,260 reverses the effects of chronic clozapine and haloperidol on midbrain dopamine neurons. Minabe Y; Ashby CR; Wang RY Brain Res; 1991 May; 549(1):151-4. PubMed ID: 1893248 [TBL] [Abstract][Full Text] [Related]
43. CCK-8 excites substantia nigra dopaminergic neurons by increasing a cationic conductance. Wu T; Wang HL Neurosci Lett; 1994 Apr; 170(2):229-32. PubMed ID: 8058194 [TBL] [Abstract][Full Text] [Related]
45. Effects of the CCK-A receptor antagonist CR 1409 on the activity of rat midbrain dopamine neurons. Zhang J; Chiodo LA; Freeman AS Peptides; 1991; 12(2):339-43. PubMed ID: 2067986 [TBL] [Abstract][Full Text] [Related]
46. The use of receptor desensitization to analyse CCKA and CCKB/gastrin receptors coupled to contraction in guinea-pig stomach muscle. Bishop LA; Gerskowitch VP; Hull RA; Shankley NP; Black JW Br J Pharmacol; 1995 Jan; 114(2):339-48. PubMed ID: 7881733 [TBL] [Abstract][Full Text] [Related]
47. Electrophysiological effects of cholecystokinin octapeptide on identified rat nigrostriatal dopaminergic neurons. Freeman AS; Chiodo LA Brain Res; 1988 Jan; 439(1-2):266-74. PubMed ID: 3359189 [TBL] [Abstract][Full Text] [Related]
48. Cholecystokinin-GABA interactions in rodent cortex: analyses of cholecystokinin effects on K(+)- and L-glutamate-induced release of [3H]GABA from rat cortical slices and cultured mouse cortical neurones. Hickling YM; Cheung NS; Larm JA; Cowen MS; Shulkes A; Beart PM Neurochem Int; 1997 Feb; 30(2):171-9. PubMed ID: 9017664 [TBL] [Abstract][Full Text] [Related]
49. Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo. Scarpignato C; Kisfalvi I; D'Amato M; Varga G Aliment Pharmacol Ther; 1996 Jun; 10(3):411-9. PubMed ID: 8791971 [TBL] [Abstract][Full Text] [Related]
50. Cholecystokinin activates orexin/hypocretin neurons through the cholecystokinin A receptor. Tsujino N; Yamanaka A; Ichiki K; Muraki Y; Kilduff TS; Yagami K; Takahashi S; Goto K; Sakurai T J Neurosci; 2005 Aug; 25(32):7459-69. PubMed ID: 16093397 [TBL] [Abstract][Full Text] [Related]
51. Forebrain projections from cholecystokininlike-immunoreactive neurons in the rat midbrain. Seroogy KB; Fallon JH J Comp Neurol; 1989 Jan; 279(3):415-35. PubMed ID: 2918078 [TBL] [Abstract][Full Text] [Related]
52. SCH 23390-induced hypophagia is blocked by the selective CCK-A receptor antagonist devazepide, but not by the CCK-B/gastrin receptor antagonist L-365,260. Cooper SJ; Barber DJ Brain Res Bull; 1990 Apr; 24(4):631-3. PubMed ID: 2141538 [TBL] [Abstract][Full Text] [Related]
53. Cholecystokinin release from the rat caudate-putamen, cortex and hippocampus is increased by activation of the D1 dopamine receptor. Brog JS; Beinfeld MC J Pharmacol Exp Ther; 1992 Jan; 260(1):343-8. PubMed ID: 1346163 [TBL] [Abstract][Full Text] [Related]
54. Clarification of the behavioral functions of peripheral and central cholecystokinin: two separate peptide pools. Crawley JN Peptides; 1985; 6 Suppl 2():129-36. PubMed ID: 3001671 [TBL] [Abstract][Full Text] [Related]
55. G alpha q/11 mediates cholecystokinin activation of the cationic conductance in rat substantia nigra dopaminergic neurons. Wu T; Wang HL J Neurochem; 1996 Mar; 66(3):1060-6. PubMed ID: 8769867 [TBL] [Abstract][Full Text] [Related]
56. The impact of a competitive and a non-competitive NMDA receptor antagonist on dopaminergic neurotransmission in the rat ventral tegmental area and substantia nigra. Wedzony K; Czyrak A; Maćkowiak M; Fijał K Naunyn Schmiedebergs Arch Pharmacol; 1996 Apr; 353(5):517-27. PubMed ID: 8740145 [TBL] [Abstract][Full Text] [Related]
57. Behavioural evidence for cholecystokinin-dopamine D1 receptor interactions in the rat. Van Kampen J; Frydryszak H; Stoessl AJ Eur J Pharmacol; 1996 Feb; 298(1):7-15. PubMed ID: 8867913 [TBL] [Abstract][Full Text] [Related]
58. [Behavioral and neurochemical study on the role of the brain cholecystokinin system in anxiety]. Izumi T Hokkaido Igaku Zasshi; 1998 Sep; 73(5):463-73. PubMed ID: 9846276 [TBL] [Abstract][Full Text] [Related]
59. Effects of administration of cholecystokinin into the VTA on DA overflow in nucleus accumbens and amygdala of freely moving rats. Hamilton ME; Freeman AS Brain Res; 1995 Aug; 688(1-2):134-42. PubMed ID: 8542299 [TBL] [Abstract][Full Text] [Related]
60. Noxious stimulation accelerated the expression of c-fos protooncogene in cholecystokininergic and dopaminergic neurons in the ventral tegmental area. Ma QP; Zhou Y; Han JS Peptides; 1993; 14(3):561-6. PubMed ID: 8332552 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]